Nutex Health Responds to Short Seller Report
Nutex Health (NASDAQ: NUTX), a physician-led healthcare system operating 24 micro hospitals and HOPDs across 11 states, has issued a formal response to a recent short seller report. The company strongly refutes allegations regarding its collection process, stating that the report contains misrepresentations and demonstrates a misunderstanding of their business model.
Nutex Health emphasizes its robust internal process for coding, billing, and handling medical claims through independent dispute resolution when necessary. The company plans to provide additional updates in its upcoming Q2 2025 earnings release and Form 10-Q, expected by August 14, 2025.
Nutex Health (NASDAQ: NUTX), un sistema sanitario guidato da medici che gestisce 24 micro ospedali e HOPD in 11 stati, ha rilasciato una risposta ufficiale a un recente rapporto di venditori allo scoperto. L'azienda nega fermamente le accuse relative al suo processo di riscossione, affermando che il rapporto contiene rappresentazioni errate e dimostra una scarsa comprensione del loro modello di business.
Nutex Health sottolinea il suo solido processo interno per la codifica, la fatturazione e la gestione delle richieste mediche tramite una risoluzione indipendente delle controversie quando necessario. L'azienda prevede di fornire ulteriori aggiornamenti nel suo prossimo comunicato sugli utili del secondo trimestre 2025 e nel modulo 10-Q, attesi entro il 14 agosto 2025.
Nutex Health (NASDAQ: NUTX), un sistema de salud dirigido por médicos que opera 24 micro hospitales y HOPD en 11 estados, ha emitido una respuesta formal a un reciente informe de vendedores en corto. La compañÃa rechaza categóricamente las acusaciones relacionadas con su proceso de cobro, afirmando que el informe contiene representaciones erróneas y demuestra un malentendido de su modelo de negocio.
Nutex Health enfatiza su sólido proceso interno para la codificación, facturación y manejo de reclamaciones médicas a través de resolución independiente de disputas cuando es necesario. La compañÃa planea proporcionar actualizaciones adicionales en su próximo informe de ganancias del segundo trimestre de 2025 y en el Formulario 10-Q, esperado para el 14 de agosto de 2025.
Nutex Health (NASDAQ: NUTX)ëŠ� 11ê°� 주ì—ì„� 24ê°œì˜ ë§ˆì´í¬ë¡œ 병ì›ê³� HOPDë¥� ìš´ì˜í•˜ëŠ” ì˜ì‚¬ ì£¼ë„ ì˜ë£Œ 시스템으ë¡�, 최근 공매ë„ìž ë³´ê³ ì„œì— ëŒ€í•� ê³µì‹ ìž…ìž¥ì� 발표했습니다. 회사ëŠ� 수금 ì ˆì°¨ì™€ ê´€ë ¨ëœ ì£¼ìž¥ë“¤ì„ ê°•ë ¥íž� ë¶€ì�하며, 해당 ë³´ê³ ì„œì— ì˜¤í•´ì� 소지가 있는 ë‚´ìš©ì� í¬í•¨ë˜ì–´ ìžˆê³ ë¹„ì¦ˆë‹ˆìŠ¤ 모ë¸ì—� 대í•� 오해ë¥� ë³´ì—¬ì¤€ë‹¤ê³ ë°í˜”습니ë‹�.
Nutex HealthëŠ� 코딩, ì²êµ¬ ë°� ì˜ë£Œ ì²êµ¬ 처리ë¥� 위한 ê²¬ê³ í•� ë‚´ë¶€ 프로세스ë¥� 강조하며, í•„ìš”ì‹� ë…립ì ì¸ ë¶„ìŸ í•´ê²° ì ˆì°¨ë¥� 진행한다ê³� 설명했습니다. 회사ëŠ� 2025ë…� 8ì›� 14ì¼ê¹Œì§€ ì˜ˆì •ë� 2025ë…� 2분기 실ì 발표 ë°� 10-Q ì–‘ì‹ì—서 추가 ì—…ë°ì´íЏë¥� ì œê³µí•� 계íšìž…니ë‹�.
Nutex Health (NASDAQ : NUTX), un système de santé dirigé par des médecins exploitant 24 micro-hôpitaux et HOPD dans 11 états, a publié une réponse officielle à un récent rapport d'investisseurs vendeurs à découvert. L'entreprise rejette fermement les allégations concernant son processus de recouvrement, affirmant que le rapport contient des informations erronées et démontre une mauvaise compréhension de leur modèle commercial.
Nutex Health souligne son processus interne solide pour la codification, la facturation et la gestion des réclamations médicales via une résolution indépendante des litiges lorsque cela est nécessaire. L'entreprise prévoit de fournir des mises à jour supplémentaires dans sa prochaine publication des résultats du deuxième trimestre 2025 et dans le formulaire 10-Q, attendue pour le 14 août 2025.
Nutex Health (NASDAQ: NUTX), ein von Ärzten geführtes Gesundheitssystem, das 24 Mikrokrankenhäuser und HOPDs in 11 Bundesstaaten betreibt, hat eine formelle Stellungnahme zu einem kürzlich veröffentlichten Bericht von Leerverkäufern abgegeben. Das Unternehmen weist die Vorwürfe bezüglich seines Inkassoprozesses entschieden zurück und erklärt, dass der Bericht Fehlinterpretationen enthält und das Geschäftsmodell missversteht.
Nutex Health betont seinen robusten internen Prozess für Kodierung, Abrechnung und Bearbeitung medizinischer Ansprüche durch unabhängige Streitbeilegung, wenn nötig. Das Unternehmen plant, weitere Updates in seinem kommenden Quartalsbericht für Q2 2025 und dem Formular 10-Q bereitzustellen, der bis zum 14. August 2025 erwartet wird.
- Company maintains a robust internal process for coding, billing, and claims resolution
- Company will provide transparency through upcoming Q2 2025 earnings release
- Company faces allegations from short sellers regarding collection processes
- Stock price likely affected by short seller attack
The Company is aware of the allegations made in a recent short seller report that attempts to call into question the Company's collection process. As previously disclosed, Nutex Health has developed a robust internal process to code, bill and, if necessary after a federally mandated negotiation period, submit eligible medical claims to independent dispute resolution.
The Company strongly disagrees with the allegations in the report and believes it is without merit. Further, the Company believes the report contains misrepresentations and conveys a misunderstanding of Nutex Health's business.Â
Nutex Health expects to provide related updates in its upcoming earnings release and Form 10-Q for the second quarter of 2025 due on or before August 14, 2025.
About Nutex Health Inc.
Headquartered in
The Hospital Division owns, develops and operates innovative health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments (HOPDs). This division owns and operates 24 facilities in 11 states.
The Population Health Management division owns and operates provider networks such as Independent Physician Associations (IPAs). Through our Management Services Organization (MSO), we provide management, administrative and other support services to our affiliated hospitals and physician groups.
Forward-Looking Statements
Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases "will", "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," "goal," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include, but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, including the interim final and final rules implemented under the No Surprises Act , economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company's ability to compete, conflicts of interest in related party transactions, regulatory matters, protection of technology, lack of industry standards, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Annual Report on Form 10-K for the year ended December 31, 2024, under the heading "Risk Factors" in Part II, Item IA thereof, and the risk factors and other cautionary statements contained in our other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release.
View original content:
SOURCE Nutex Health, Inc.